On July 23–24, 2026, an FDA advisory committee reviews several compounded peptides. If you're a patient in Dalton, Chattanooga, or Northwest Georgia, here's exactly what it changes for you — and what it doesn't.
See the live tracker What it means for meOver July 23–24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will vote on whether several compounded peptides belong on the list of substances that licensed pharmacies can compound. You'll see loud headlines — "FDA panel backs" or "FDA panel rejects" this or that peptide. Before you read too much into either, hold onto one fact: a committee vote is a recommendation to the FDA, not a rule.
Even a decisive vote doesn't change the law the next morning. For anything to actually shift, the FDA has to publish a proposed rule, open a second public comment period, and then issue a final rule — a process that routinely runs more than a year. So whatever the committee recommends this week, nothing on your Limitless protocol changes on the day of the vote. We told the FDA where we stand months ago; we filed our physician comment in May and it's in the public record.
The committee reviews four substances on Thursday and three on Friday. For each, the FDA evaluated a specific medical use — which is not the same as the way these compounds get marketed online. Here's the honest map:
Two things worth knowing going in. First, each substance is nominated in two forms — free base and acetate — which the committee can vote on separately, so you may see split outcomes. Second, the FDA's own scientific briefing documents read skeptical on all seven. That's precisely why we practice the way we do: prescribe inside defensible indications, source only through licensed 503A/503B pharmacies, and say plainly where the evidence is thin.
The peptides Dr. Hare actively prescribes are matched to the patient and the clinical goal, not to a marketed use — and your FDA-approved therapies (testosterone, tesamorelin) aren't part of this review at all. We track every vote as it lands on our PCAC Watch page.
Nothing you're currently on changes on the strength of a committee vote. If any final FDA action ever affects a specific therapy down the line, your physician contacts you directly with a plan before anything changes. You will never learn about a change to your care from a headline.
Testosterone, tesamorelin, and the other approved medications on your protocol are not part of this review. This meeting is only about specific compounded peptide bulk substances being considered for the 503A list.
Nothing about where or how you're seen changes. Limitless is at 1502 Dug Gap Road in Dalton — about 25–30 minutes south of Chattanooga via I-75. Tennessee Valley patients keep the same schedule, the same physician, the same plan.
We post the recorded votes and a plain-language interpretation within 48 hours of each session — no spin, no fear, no "act now" marketing. If it changes something for you, we'll say so. If it doesn't, we'll say that too.
The regulatory noise is loud this week. Your care doesn't have to be. If you're weighing any of this against your own plan — or you're a Northwest Georgia or Chattanooga-area patient deciding where to start — talk to the physician who reads your labs.
Book a consultation Follow the tracker